Literature DB >> 28000879

High-mobility group box 1 is overexpressed in cervical carcinoma and promotes cell invasion and migration in vitro.

Xiaoao Pang1, Yao Zhang1, Shulan Zhang1.   

Abstract

The present study aimed to investigate the expression of high-mobility group box 1 protein (HMGB1) in cervical carcinoma and explore whether or not HMGB1 promotes cervical carcinoma cell invasion and migration in vitro and the related mechanism. HMGB1, nuclear factor-κB (NF-κB), E-cadherin and N-cadherin protein expression was analyzed in tissues from 48 cervical carcinomas, 51 cervical intraepithelial neoplasia (CIN) and tissues from 24 healthy controls using immunohistochemistry. HeLa cells were treated with different concentrations of HMGB1 (0, 10, 100, and 1,000 ng/ml) at different time-points (0, 24, 48 and 72 h), and changes in cell morphology and biological behaviors were observed. Changes in the expression levels of E-cadherin, N-cadherin, NF-κB and the inhibitor κB (IκB) in the treated cells were detected by western blot analysis and real-time PCR. HMGB1 expression exhibited a gradually increasing trend in the normal cervical tissues, CIN and cervical cancer, and there was statistical significance between the three groups (P<0.05). HMGB1 expression level was associated with FIGO stage, lymph node metastasis and differentiation (P<0.05). HMGB1 expression was positively related to N-cadherin and NF-κB; and HMGB1 had a negative relationship with E-cadherin. HMGB1 stimulation caused HeLa cells to lose cell polarity and transition from epithelial cells into spindle-shaped cells with sparse cell-cell junctions. The expression levels of E-cadherin and IκB in the cytoplasm were reduced, while N-cadherin expression was increased. The level of NF-κB expression in the nucleus was also increased. Treatment with NF-κB inhibitor (BAY11-7082) and receptor for advanced glycation end products (RAGE) antagonist (anti-RAGE) significantly suppressed HMGB1‑mediated epithelial-to-mesenchymal transition in the HeLa cervical cancer cells. The results suggest that HMGB1 is associated with outcomes of cervical cancer and promotes subsequent invasion and metastasis of cervical cancer cells by activating the NF-κB signaling pathway. This potential mechanism could be an important determinant of cervical cancer metastasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28000879     DOI: 10.3892/or.2016.5317

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  13 in total

1.  ResolvinD1 attenuates high-mobility group box 1-induced epithelial-to-mesenchymal transition in nasopharyngeal carcinoma cells.

Authors:  Pingli Yang; Shan Chen; Gang Zhong; Yan Wang; Weijia Kong; Yanjun Wang
Journal:  Exp Biol Med (Maywood)       Date:  2019-11-01

2.  MicroRNA-34a directly targets high-mobility group box 1 and inhibits the cancer cell proliferation, migration and invasion in cutaneous squamous cell carcinoma.

Authors:  Shanshan Li; Chengqun Luo; Jun Zhou; Yong Zhang
Journal:  Exp Ther Med       Date:  2017-10-02       Impact factor: 2.447

Review 3.  The RAGE/multiligand axis: a new actor in tumor biology.

Authors:  Armando Rojas; Ivan Schneider; Cristian Lindner; Ileana Gonzalez; Miguel A Morales
Journal:  Biosci Rep       Date:  2022-07-29       Impact factor: 3.976

4.  High Mobility Group Box 1 Protein in Osteoarthritic Knee Tissue and Chondrogenic Progenitor Cells: An Ex Vivo and In Vitro Study.

Authors:  Gunar Wagner; Christoph Lehmann; Christa Bode; Nicolai Miosge; Andrea Schubert
Journal:  Cartilage       Date:  2019-03-26       Impact factor: 4.634

5.  RAGE-specific single chain Fv for PET imaging of pancreatic cancer.

Authors:  Hye-Yeong Kim; Xiaolei Wang; Rui Kang; Daolin Tang; Brian A Boone; Herbert J Zeh; Michael T Lotze; W Barry Edwards
Journal:  PLoS One       Date:  2018-03-12       Impact factor: 3.240

Review 6.  Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in Cancer Progression.

Authors:  Ali H El-Far; Grazyna Sroga; Soad K Al Jaouni; Shaker A Mousa
Journal:  Int J Mol Sci       Date:  2020-05-20       Impact factor: 5.923

7.  Impact of the Receptor for Advanced Glycation End Products Genetic Polymorphisms on the Progression in Uterine Cervical Cancer.

Authors:  Chung-Yuan Lee; Soo-Cheen Ng; Yi-Hsuan Hsiao; Shun-Fa Yang; Chun-Fang Hsu; Po-Hui Wang
Journal:  J Cancer       Date:  2018-10-10       Impact factor: 4.207

Review 8.  HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma.

Authors:  Yanbin Wang; Zhaoqiang Jiang; Jianing Yan; Shibo Ying
Journal:  Dis Markers       Date:  2019-02-12       Impact factor: 3.434

9.  NF-κB pathway link with ER stress-induced autophagy and apoptosis in cervical tumor cells.

Authors:  Xiaolan Zhu; Li Huang; Jie Gong; Chun Shi; Zhiming Wang; Bingkun Ye; Aiguo Xuan; Xiaosong He; Dahong Long; Xiao Zhu; Ningfang Ma; Shuilong Leng
Journal:  Cell Death Discov       Date:  2017-09-11

10.  LncRNA NNT-AS1 contributes to the cisplatin resistance of cervical cancer through NNT-AS1/miR-186/HMGB1 axis.

Authors:  Yanjie Liu; Ruixia Guo; Yuhuan Qiao; Liping Han; Mingzhu Liu
Journal:  Cancer Cell Int       Date:  2020-05-24       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.